<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878642</url>
  </required_header>
  <id_info>
    <org_study_id>13-184</org_study_id>
    <nct_id>NCT02878642</nct_id>
  </id_info>
  <brief_title>Adherence to Dolutegravir and Outcome</brief_title>
  <acronym>DOLUTECAPS</acronym>
  <official_title>Cohort Study to Assess Electronic-caps Defined Adherence Patterns - Virological Outcome Relationship Amongst HIV-1 Infected Subjects Receiving Dolutegravir-Based Antiretroviral Therapy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main assumption is that the dolutegravir can get virologic suppression to suboptimal
      adherence levels (between 80 and 95%, and after treatment interruptions) where other
      molecules are not capable, due to their pharmacokinetic/pharmacodynamic (pardonnance).

      While the investigators goal is not to compare molecules (study with one arm) in terms of
      forgiveness, the results of this cohort in terms of forgiveness could be compared to other
      cohorts available.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date>December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to dolutegravir measured by the electronic pill boxes</measure>
    <time_frame>From baseline up to week 24</time_frame>
    <description>Calculating the total compliance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Virologic Efficacy</measure>
    <time_frame>week 24</time_frame>
    <description>Are defined as secondary virological failure condition patients to S24 a viral load above 40 copies / ml on 2 consecutive samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Genotype resistance if failure</measure>
    <time_frame>Week 16 and 24</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>HIV</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients infected with HIV-1 treated with dolutegravir at week 16 and week 24
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1

          -  Age over 18 years

          -  Information letter signed

          -  ART (antiretroviral therapy) with at least 3 active molecules

          -  Patients starting treatment with dolutegravir (na√Øve to antiretroviral treatment,
             switch, virologic failure)

        Exclusion Criteria:

          -  pregnant woman

          -  HIV-2

          -  Patient does not have responsibility for the observance of treatment (disorder of
             judgment, guardianship, institutionalization)

          -  Patient receiving aid incompatible with compliance with the use of electronic pillbox
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean Jacques PARIENTI, MD,PhD</last_name>
    <phone>02 31 06 43 20</phone>
    <phone_ext>+33</phone_ext>
    <email>parienti-jj@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Jacques PARIENTI, MD, PhD</last_name>
      <email>parienti-jj@chu-caen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

